We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier
Read MoreHide Full Article
AbbVie (ABBV - Free Report) announced a multi-year, multi-program R&D collaboration with precision medicines company, Frontier Medicines, Corp. to discover and develop innovative small molecule therapies against difficult-to-drug protein targets.
Per the deal, AbbVie will use Frontier's proprietary chemoproteomics platform to identify programs directed against E3 ligase, immunology and oncology targets, which can be developed into highly differentiated and efficacious therapeutics. For the deal, AbbVie will make an upfront payment of $55 million to Frontier while the latter will be entitled to receiveadditional milestone payments.
Per the agreement, while Frontier will take care of pre-clinical development up to a certain stage, AbbVie will re-imburse the R&D expenses. Thereafter, AbbVie will take over full responsibility for global development and commercialization activities and costs for the programs. Frontier retains an option to share development costs for some oncology programs through phase II.
AbbVie’s stock has risen 18.5% this year so far compared with an increase of 1.4% for the industry.
AbbVie has been actively pursuing partnership deals and collaborations for candidates across several therapeutic areas including oncology, immunology, neuroscience, cystic fibrosis and women’s health. Some partners include Roche (RHHBY - Free Report) for Venclexta, J&J (JNJ - Free Report) for Imbruvica and Boehringer Ingelheim for Skyriziamong others. In 2020, AbbVie signed oncology deals with Genmab (GMAB - Free Report) to jointly develop and commercialize Genmab's three early-stage investigational bispecific antibody therapeutics and China-based biotech I-Mab Biopharma for development and commercialization of lemzoparlimab for multiple cancers.
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
Image: Bigstock
AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier
AbbVie (ABBV - Free Report) announced a multi-year, multi-program R&D collaboration with precision medicines company, Frontier Medicines, Corp. to discover and develop innovative small molecule therapies against difficult-to-drug protein targets.
Per the deal, AbbVie will use Frontier's proprietary chemoproteomics platform to identify programs directed against E3 ligase, immunology and oncology targets, which can be developed into highly differentiated and efficacious therapeutics. For the deal, AbbVie will make an upfront payment of $55 million to Frontier while the latter will be entitled to receiveadditional milestone payments.
Per the agreement, while Frontier will take care of pre-clinical development up to a certain stage, AbbVie will re-imburse the R&D expenses. Thereafter, AbbVie will take over full responsibility for global development and commercialization activities and costs for the programs. Frontier retains an option to share development costs for some oncology programs through phase II.
AbbVie’s stock has risen 18.5% this year so far compared with an increase of 1.4% for the industry.
AbbVie has been actively pursuing partnership deals and collaborations for candidates across several therapeutic areas including oncology, immunology, neuroscience, cystic fibrosis and women’s health. Some partners include Roche (RHHBY - Free Report) for Venclexta, J&J (JNJ - Free Report) for Imbruvica and Boehringer Ingelheim for Skyriziamong others. In 2020, AbbVie signed oncology deals with Genmab (GMAB - Free Report) to jointly develop and commercialize Genmab's three early-stage investigational bispecific antibody therapeutics and China-based biotech I-Mab Biopharma for development and commercialization of lemzoparlimab for multiple cancers.
AbbVie currently has a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>